Home

LUKAS SCHEIBLER

CIK 1651281 · Chief Research Officer · last filed 2023-12-05

LUKAS SCHEIBLER is a Chief Research Officer who has filed 43 SEC Form 4 insider transactions across 1 company since 2018. The most recent filing, for APLS, was dated Dec 5, 2023. Across all open-market trades the lifetime net is −$3.2M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

43

Lifetime Open-Market Net

-$3.20M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Apellis Pharmaceuticals, Inc. (APLS) Delisted Chief Research Officer 78,299 $41.03 $3.21M -$3.20M 26 2023-12-05

Recent Filings

43 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-12-05 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed — -$461.5K EDGAR
2023-12-01 Apellis Pharmaceuticals, Inc. (APLS) Delisted Notice (144) −10,000 -$600.0K EDGAR
2023-09-07 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −1,756 -$75.5K EDGAR
2023-09-06 Apellis Pharmaceuticals, Inc. (APLS) Delisted Notice (144) −1,756 -$75.5K EDGAR
2023-02-22 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed +9,171 -$41.8K EDGAR
2023-02-14 Apellis Pharmaceuticals, Inc. (APLS) Delisted Tax (F) −678 -$34.7K EDGAR
2023-01-30 Apellis Pharmaceuticals, Inc. (APLS) Delisted Tax (F) −542 -$28.6K EDGAR
2023-01-24 Apellis Pharmaceuticals, Inc. (APLS) Delisted Tax (F) −2,015 -$104.9K EDGAR
2023-01-17 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +22,580 $0 EDGAR
2022-05-31 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −11,875 -$430.0K EDGAR
Showing 1–10 of 43
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.